Clinical Research Of Huanglong Kechuan Capsule In The Treatment Of Chronic Obstructive Pulmonary Disease At Stable Stage

Objective:To evaluate the clinical efficacy of Huanglong Kechuan capsule in treating chronic obstructive pulmonary disease at stable stage,based on the changes of the lung function,symptom score,6MWD,COPD assessment test(CAT)questionnaire score.Methods:Divide sixty-two patients with COPD at stable stage into two groups:treatment group(n=31)and control group(n=31).The control group used salmeterol xinafoate and fluticasone propionate powder for inhalation,while the treatment group was added Huanglong Ke Chuan Capsule on the basis of the control group.The course of treatment of the two groups was three months.After treatment,comparison the changes of TCM symptom classification quantitative score,lung function,6MWD,dyspnea scores,CAT score and frequency of AECOPD before and after to evaluate the efficacy.Results:1.General information:Two groups of gender,age and course of disease were not significantly different(P>0.05),comparable.2.Symptom score and efficacy comparison:The symptom scores of the two groups were improved after treatment,and the treatment group was better than that in the control group(P<0.05).The total effective rate of treatment group is 83.33%,while the total effective rate of control group is 63.33%.The difference of total effective rate between the two groups is statistically significant(P<0.05).The results shows that the treatment group in improving TCM syndrome score and symptoms better than the control group.3.Lung function,6MWD,CAT score:Two groups of lung function index,6 minute walk distance and CAT score after treatment were significantly different from those before treatment(P<0.05).The curative effect of the treatment group was better than that of the control group(P<0.05).It is showed that both groups can improve the lung function index,6MWD and CAT score,the degree of improvement of treatment group is better than the control group.4.Dyspnea scores:The dyspnea scores of treatment group after treatment improved more significantly than before treatment.Compared with the control group,the dyspnea scores of treatment group after treatment improved more obviously.The difference of dyspnea scores between the two groups is statistically significant(P<0.05).It shows that the treatment group in improving dyspnea is better than the control group.5.Frequency of AECOPD:The frequency of AECOPD in the treatment group is lower than that of the control group,the difference was statistically significant(P<0.05).It shows that the treatment group in reducing the frequency of AECOPD is better than the control group.Conclusion:The research indicates that the efficacy of the treatment Huanglong Kechuan capsule of COPD at stable stage is significant,it can improve the clinical symptoms and lung function,reduce the frequency of AECOPD,impove quality of live.It is worth popularizing in clinical application.